Novel drug-eluting stent system prevents restenosis
Pippa Murdie
This article has no abstract so we have provided the first paragraph of the full text.
Drug-eluting stents (DESs) have been shown to reduce the incidence of in-stent restenosis significantly compared with conventional bare-metal stents. Restenosis remains significant in patients at high risk for this occurrence, however, and there are concerns that the use of fixed drugs and doses in different patient subgroups could reduce the efficacy of DESs, while the use of polymer coatings could increase late complications. The Munich-based ISAR PROJECT tested a novel DES system that allows the physician to choose a patient-specific drug and dose, and permits a polymer-free stent coating to be used.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
